Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration
- PMID: 19744982
- DOI: 10.1093/jac/dkp331
Pharmacokinetics of novel antimicrobial cationic peptides NAB 7061 and NAB 739 in rats following intravenous administration
Abstract
Objectives: To determine the disposition of novel antimicrobial cationic peptides NAB 7061 and NAB 739 following intravenous administration in rats.
Methods: Sprague-Dawley rats received a single intravenous bolus of 1.0 mg/kg NAB 7061 or NAB 739. Plasma concentrations of NAB 7061 or NAB 739 were determined by HPLC or liquid chromatography-mass spectrometry. The pharmacokinetic parameters of NAB 7061 and NAB 739 were calculated using non-compartmental analysis.
Results: Corresponding total body clearance, volume of distribution at steady state and terminal half-life of NAB 7061 and NAB 739 averaged 3.84 and 2.63 mL/min/kg, 339 and 222 mL/kg, and 66.2 and 69.0 min, respectively. Approximately 7.16% and 19.4% of the dose was eliminated in an unchanged form via the urine in 24 h for NAB 7061 and NAB 739, respectively.
Conclusions: While both compounds had generally similar pharmacokinetics to colistin, even minor alterations in the chemical structures appear to have an impact on their pharmacokinetics, especially on their clearance by the kidney. There are also substantial differences in relation to the relative contributions of renal and non-renal clearance to overall elimination from the body.
Similar articles
-
Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.J Antimicrob Chemother. 2004 May;53(5):837-40. doi: 10.1093/jac/dkh167. Epub 2004 Mar 24. J Antimicrob Chemother. 2004. PMID: 15044428
-
Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses.J Antimicrob Chemother. 2010 Aug;65(8):1753-8. doi: 10.1093/jac/dkq183. Epub 2010 May 27. J Antimicrob Chemother. 2010. PMID: 20507861
-
Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats.Biopharm Drug Dispos. 2009 Jul;30(5):221-8. doi: 10.1002/bdd.657. Biopharm Drug Dispos. 2009. PMID: 19544289
-
Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.Cancer Chemother Pharmacol. 2008 May;61(6):1037-44. doi: 10.1007/s00280-007-0563-z. Epub 2007 Sep 1. Cancer Chemother Pharmacol. 2008. PMID: 17768626
-
Pharmacokinetics of Polymyxins in Animals.Adv Exp Med Biol. 2019;1145:89-103. doi: 10.1007/978-3-030-16373-0_7. Adv Exp Med Biol. 2019. PMID: 31364073 Review.
Cited by
-
Antibiotics and bacterial resistance in the 21st century.Perspect Medicin Chem. 2014 Aug 28;6:25-64. doi: 10.4137/PMC.S14459. eCollection 2014. Perspect Medicin Chem. 2014. PMID: 25232278 Free PMC article. Review.
-
Rescuing the Last-Line Polymyxins: Achievements and Challenges.Pharmacol Rev. 2021 Apr;73(2):679-728. doi: 10.1124/pharmrev.120.000020. Pharmacol Rev. 2021. PMID: 33627412 Free PMC article. Review.
-
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.Antimicrob Agents Chemother. 2010 Aug;54(8):3341-6. doi: 10.1128/AAC.01439-09. Epub 2010 May 17. Antimicrob Agents Chemother. 2010. PMID: 20479195 Free PMC article.
-
Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.J Antibiot (Tokyo). 2017 Apr;70(4):386-394. doi: 10.1038/ja.2016.146. Epub 2017 Jan 11. J Antibiot (Tokyo). 2017. PMID: 28074057 Review.
-
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids.J Med Chem. 2022 Dec 8;65(23):15878-15892. doi: 10.1021/acs.jmedchem.2c01528. Epub 2022 Nov 18. J Med Chem. 2022. PMID: 36399613 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources